Exiqon Inks Exclusive Prostate Cancer Biomarker Deal With Aarhus University Hospital | GenomeWeb

NEW YORK (GenomeWeb) – Exiqon yesterday announced that it has exclusively licensed two sets of microRNA-based prostate cancer biomarkers from Denmark's Aarhus University Hospital.

One biomarker profile relates to urine-based, non-invasive diagnosis of prostate cancer; the other set of biomarkers comes from tissue samples and is relevant to patient stratification for improved treatment selection. Exiqon said in a statement that it will validate the biomarkers in both retrospective and prospective studies.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.